Title : A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.

Pub. Date : 2011 Feb

PMID : 21264552






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BCR-ABL kinase domain mutations were sequentially analyzed in a patient with chronic myeloid leukemia (CML) who exhibited repeated B-lymphoid blast crisis (CML-BC) during treatment with imatinib and dasatinib. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 The in vitro analysis using K294RGG mutant BCR-ABL-expressing 32D cells revealed that K294RGG mutation was imatinib resistant but dasatinib sensitive. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
3 However, after the dasatinib treatment, wild-type BCR-ABL clone disappeared and T315I or F317L mutation was acquired in G250E and Y253H mutant clones on the same allele without the emergence of each sole mutant clone. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens